Dr. Vahdat is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1 Medical Center Dr
Lebanon, NH 03756Phone+1 603-650-5747
Education & Training
Massachusetts Institute of Technology, Sloan School of ManagementMBA, Business, 2012 - 2014
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1991 - 1994
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1987 - 1990- Icahn School of Medicine at Mount SinaiClass of 1987
Certifications & Licensure
NH State Medical License 2022 - 2026
NY State Medical License 1988 - 2025
VT State Medical License 2023 - 2024
CT State Medical License 2017 - 2022- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 203 citationsFirst-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors.Alexander Starodub, Allyson J. Ocean, Manish A. Shah, Michael J. Guarino, Vincent J. Picozzi
Clinical Cancer Research. 2015-05-05 - 195 citationsEfficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.Aditya Bardia, Ingrid A. Mayer, Jennifer R. Diamond, Rebecca L. Moroose, Steven J. Isakoff
Journal of Clinical Oncology. 2017-03-14 - 147 citationsSacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokineticsAllyson J. Ocean, Alexander Starodub, Aditya Bardia, Linda T. Vahdat, Steven J. Isakoff
Cancer. 2017-10-01
Press Mentions
Copper Depletion Combats Metastatic Recurrence in High-Risk TNBCSeptember 9th, 2024- This Clinical Trial Is Testing a Pill for Triple-Negative Breast CancerAugust 27th, 2024
- Post-ASCO News Alert: AstraZeneca’s/Merck’s Lynparza Use in Niche HR+ gBRCA-Mutant Breast Cancer Subgroup Could Compete with VerzenioJune 21st, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
